Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2.
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2.
复制标题
DOI：
10.3390/biomedicines10010171
复制
发表时间：
2022-01-13
期刊：
影响因子：
4.7
通讯作者：
Nowacki TM
中科院分区：
文献类型：
--
作者：
Vollenberg R;Tepasse PR;Kühn JE;Hennies M;Strauss M;Rennebaum F;Schomacher T;Boeckel G;Lorentzen E;Bokemeyer A;Nowacki TM
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）是2019年冠状病毒病（COVID-19）大流行的原因。疫苗接种被认为是遏制这一大流行病的核心方法。目前还没有足够的证据表明这些疫苗在免疫抑制性炎症性肠病（IBD）患者中的疗效。本研究的目的是研究免疫抑制IBD患者在COVID-19 mRNA疫苗接种后的体液反应。在这项前瞻性研究中，IgG抗体水平（AB）对SARS-CoV-2受体结合域（刺突蛋白）进行了定量测定。为了评估潜在的中和能力，在IBD患者（n = 95）和健康对照（n = 38）中采用SARS-CoV-2替代中和试验（sVNT）。在第一次/第二次接种前和第二次接种后3/6个月检查血清。患者在第二次疫苗接种前（sVNT p < 0.001; AB p <0.001）和第二次疫苗接种后3个月（sVNT p = 0.002; AB p = 0.001）和6个月（sVNT p = 0.062; AB p = 0.061）均显示较低的sVNT（%）和IgG-S（Au/mL）AB。尽管第二次接种后3个月两组的血清转化率（sVNT，IgG-S）无差异，但第二次接种后6个月观察到显著差异（sVNT p = 0.045）。在第二次疫苗接种前和接种后三个月，接受抗肿瘤坏死因子（TNF）药物治疗的患者的AB值显著低于健康受试者。总之，对于接受抗TNF治疗的IBD患者，应讨论早期加强疫苗接种。
Severe acute respiratory syndrome coronovirus-2 (SARS-CoV-2) is the cause of the coronavirus disease 2019 (COVID-19) pandemic. Vaccination is considered the core approach to containing the pandemic. There is currently insufficient evidence on the efficacy of these vaccines in immunosuppressed inflammatory bowel disease (IBD) patients. The aim of this study was to investigate the humoral response in immunosuppressed IBD patients after COVID-19 mRNA vaccination. In this prospective study, IgG antibody levels (AB) against the SARS-CoV-2 receptor-binding domain (spike-protein) were quantitatively determined. For assessing the potential neutralizing capacity, a SARS-CoV-2 surrogate neutralization test (sVNT) was employed in IBD patients (n = 95) and healthy controls (n = 38). Sera were examined prior to the first/second vaccination and 3/6 months after second vaccination. Patients showed lower sVNT (%) and IgG-S (AU/mL) AB both before the second vaccination (sVNT p < 0.001; AB p < 0.001) and 3 (sVNT p = 0.002; AB p = 0.001) and 6 months (sVNT p = 0.062; AB p = 0.061) after the second vaccination. Although seroconversion rates (sVNT, IgG-S) did not differ between the two groups 3 months after second vaccination, a significant difference was seen 6 months after second vaccination (sVNT p = 0.045). Before and three months after the second vaccination, patients treated with anti-tumor necrosis factor (TNF) agents showed significantly lower AB than healthy subjects. In conclusion, an early booster shot vaccination should be discussed for IBD patients on anti-TNF therapy.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
13.8
作者：
Nasserie T;Hittle M;Goodman SN
通讯作者：
Goodman SN
影响因子：
29.4
作者：
Pozdnyakova V;Botwin GJ;Sobhani K;Prostko J;Braun J;Mcgovern DPB;Melmed GY;Appel K;Banty A;Feldman E;Ha C;Kumar R;Lee S;Rabizadeh S;Stein T;Syal G;Targan S;Vasiliauskas E;Ziring D;Debbas P;Hampton M;Mengesha E;Stewart JL;Frias EC;Cheng S;Ebinger J;Figueiredo JC;Boland B;Charabaty A;Chiorean M;Cohen E;Flynn A;Valentine J;Fudman D;Horizon A;Hou J;Hwang C;Lazarev M;Lum D;Fausel R;Reddy S;Mattar M;Metwally M;Ostrov A;Parekh N;Raffals L;Sheibani S;Siegel C;Wolf D;Younes Z
通讯作者：
Younes Z
影响因子：
28.3
作者：
Gorbalenya, Alexander E.;Baker, Susan C.;Ziebuhr, John
通讯作者：
Ziebuhr, John
影响因子：
11.1
作者：
Deer RR;Rock MA;Vasilevsky N;Carmody L;Rando H;Anzalone AJ;Basson MD;Bennett TD;Bergquist T;Boudreau EA;Bramante CT;Byrd JB;Callahan TJ;Chan LE;Chu H;Chute CG;Coleman BD;Davis HE;Gagnier J;Greene CS;Hillegass WB;Kavuluru R;Kimble WD;Koraishy FM;Köhler S;Liang C;Liu F;Liu H;Madhira V;Madlock-Brown CR;Matentzoglu N;Mazzotti DR;McMurry JA;McNair DS;Moffitt RA;Monteith TS;Parker AM;Perry MA;Pfaff E;Reese JT;Saltz J;Schuff RA;Solomonides AE;Solway J;Spratt H;Stein GS;Sule AA;Topaloglu U;Vavougios GD;Wang L;Haendel MA;Robinson PN
通讯作者：
Robinson PN